Neurothera Labs Inc.
NTLX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -5.98M | -5.44M | -4.90M | -3.33M | -3.33M |
| Total Depreciation and Amortization | 135.00K | 140.50K | 146.00K | 187.00K | 187.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.15M | 1.91M | 1.68M | 163.00K | 163.00K |
| Change in Net Operating Assets | 1.16M | 826.00K | 491.00K | 326.00K | 326.00K |
| Cash from Operations | -2.54M | -2.56M | -2.59M | -2.66M | -2.66M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 830.00K | 770.00K | 710.00K | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -5.00K | -5.00K |
| Cash from Investing | 830.00K | 770.00K | 710.00K | -5.00K | -5.00K |
| Total Debt Issued | 1.14M | 1.14M | 1.14M | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.39M | 1.85M | 2.31M | 2.58M | 2.58M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.53M | 2.99M | 3.45M | 2.58M | 2.58M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -35.00K | -35.00K |
| Net Change in Cash | 823.00K | 1.20M | 1.57M | -122.00K | -122.00K |